The development of new Point of Care Testing (POCT) assays, particularly those utilizing CRISPR or Time-Resolved Fluorescence (TRF), involves analyzing massive datasets. Robotic Process Automation (RPA) accelerates this R&D cycle. Bots can automate the structuring of clinical trial data, run thousands of simulated thermal cycling scenarios, and compile research findings. By freeing scientists from data entry, RPA allows IVD researchers to focus on breakthrough innovations, drastically reducing the time-to-market for new diagnostics.